Document Type : Original Article


1 Pharmacy Departement, Mokolo District Hospital, Far-North Region, Cameroon

2 Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Yaounde, Cameroon

3 Departement of Surgery and Sub-Specialties, Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Yaounde, Cameroon

4 Mayo Darle Sub-Divisional Hospital, Mayo Darle, Cameroon

5 Departement of Internal Medicine and Sub-Specialities, Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Yaounde, Cameroon

6 Departement of Physiology, Biochemistry and Pharmacology, Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Yaounde, Cameroon


Background: Infections due to the hepatitis B (HBV) and hepatitis C (HCV) viruses constitute a global public health problem. Although screening of these infections remains a pivotal tool for timely detection and management of carriers, this preventive measure has been neglected in Africa.
Objective: The current study determined the prevalence of hepatitis B surface antigen (HBsAg) and anti-HCV as well as their risk factors through a screening campaign organized in a rural setting in northern Cameroon.
Methods: A cross-sectional analytical study was conducted during a screening campaign for viral hepatitis organized at the Mokolo District Hospital, Cameroon, from January 19, 2017 to February 27, 2017. Sociodemographic data from all consenting participants was collected and examined for signs of chronic liver disease. Participants were then screened for HBsAg and anti-HCV using a rapid diagnostic test (ACON®).
Results: Of the 364 participants enrolled, 28.6% tested positive for HBsAg and 2.2% for anti-HCV. All HBsAg-positive and anti-HCV-positive individuals were asymptomatic and unaware of their infection status prior to testing. None of the socio-demographic factors assessed was associated with a positive HbsAg status.
Conclusion: HBV and HCV infections are endemic in this rural health district. Participants who tested positive were apparently healthy and completely unaware of their infection status. Transmission of the hepatitis virus may be a public health concern in this district. It is recommended that community health education activities on preventive measures for HBV and HCV infections, regular screening for disease surveillance, and close follow-up of disease progression in these asymptomatic individuals be conducted.


  1. Lemoine M, Eholie S, Lacombe K. Reducing the neglected burden of viral hepatitis in Africa: strategies for a global approach. J Hepatol. 2015;62(2):469-476. doi:10.1016/j.jhep.2014.10.008.
  2. World Health Organization. Global hepatitis report, 2017. Geneva: World Health Organization; 2017.
  3. Breakwell L, Tevi-Benissan C, Childs L, Mihigo R, Tohme R. The status of hepatitis B control in the African region. Pan Afr Med J. 2017;27(Suppl 3):17. doi:10.11604/pamj.supp.2017.27.3.11981.
  4. Tran TT. Management of hepatitis B in pregnancy: weighing the options. Cleve Clin J Med. 2009;76 Suppl 3:S25-29. doi:10.3949/ccjm.76.s3.06.
  5. Dwivedi M, Misra SP, Misra V, et al. Seroprevalence of hepatitis B infection during pregnancy and risk of perinatal transmission. Indian J Gastroenterol. 2011;30(2):66-71. doi:10.1007/s12664-011-0083-y.
  6. Fomulu NJ, Morfaw FL, Torimiro JN, Nana P, Koh MV, William T. Prevalence, correlates and pattern of Hepatitis B among antenatal clinic attenders in Yaounde-Cameroon: is perinatal transmission of HBV neglected in Cameroon? BMC Pregnancy Childbirth. 2013;13:158. doi:10.1186/1471-2393-13-158.
  7. Cisneros-Castolo M, Hernandez-Ruiz L, Ibarra-Robles IE, Fernandez-Garate RH, Escobedo-De La Pena J. Prevalence of hepatitis B virus infection and related risk factors in a rural community of Mexico. Am J Trop Med Hyg. 2001;65(6):759- 763. doi:10.4269/ajtmh.2001.65.759.
  8. Rabiu KA, Akinola OI, Adewunmi AA, Omololu OM, Ojo TO. Risk factors for hepatitis B virus infection among pregnant women in Lagos, Nigeria. Acta Obstet Gynecol Scand. 2010;89(8):1024-1028. doi:10.3109/00016349.2010.482580.
  9. Obi SN, Onah HE, Ezugwu FO. Risk factors for hepatitis B infection during pregnancy in a Nigerian obstetric population. J Obstet Gynaecol. 2006;26(8):770-772. doi:10.1080/01443610600963986.
  10. Barth RE, Huijgen Q, Taljaard J, Hoepelman AI. Hepatitis B/C and HIV in sub-Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and meta-analysis. Int J Infect Dis. 2010;14(12):e1024-1031. doi:10.1016/j.ijid.2010.06.013.
  11. European Liver Patients Association (ELPA). Report on hepatitis patient self-help in Europe. Accessed May 16, 2017.
  12. Institute of Medicine Committee on the P, Control of Viral Hepatitis I. In: Colvin HM, Mitchell AE. Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C. Washington (DC): National Academies Press; 2010.
  13. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212-2219. doi:10.1016/j.vaccine.2011.12.116.
  14. Madhava V, Burgess C, Drucker E. Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. Lancet Infect Dis. 2002;2(5):293-302. doi:10.1016/S1473-3099(02)00264-5.
  15. World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva; WHO Press; 2015.
  16. World Health Organization. Guidelines on hepatitis B and C testing. Geneva: World Health Organization; 2017.
  17. Bigna JJ, Amougou MA, Asangbeh SL, et al. Seroprevalence of hepatitis B virus infection in Cameroon: a systematic review and meta-analysis. BMJ Open. 2017;7(6):e015298. doi:10.1136/bmjopen-2016-015298.
  18. Bigna JJ, Amougou MA, Asangbeh SL, Kenne AM, Nansseu JR. Seroprevalence of hepatitis C virus infection in Cameroon: a systematic review and meta-analysis. BMJ Open. 2017;7(8):e015748. doi:10.1136/bmjopen-2016-015748.
  19. World Health Organization. Expanded Programme on Immunization: Report of the 14th global Advisory Group. Geneva: World Health Organization; 1991
  20. Rey-Cuille MA, Njouom R, Bekondi C, et al. Hepatitis B virus exposure during childhood in Cameroon, Central African Republic and Senegal after the integration of HBV vaccine in the expanded program on immunization. Pediatr Infect Dis J. 2013;32(10):1110-1115. doi:10.1097/INF.0b013e31829be401.
  21. Stockdale AJ, Geretti AM. Chronic hepatitis B infection in sub- Saharan Africa: a grave challenge and a great hope. Trans R Soc Trop Med Hyg. 2015;109(7):421-422. doi:10.1093/trstmh/trv044.
  22. Annuaire Médical du Cameroun - District Sanitaire Mokolo. Available from: Accessed May 16, 2017.
  23. World Health Organization. Relevé épidémiologique hebdomadaire. Wkly Epidemiol Rec. 2009;84(40):405-420.
  24. Tchango GAN. L’accouchement à domicile au Cameroun. Disparités spatiales et essai d’explication. Proceeding of the 7th African Conference on Population: Johannesburg; 2015.
  25. Noah DN, Andoulo FA, Essoh BVM, Ayissi GN, Bagnaka SA, Biwole Sida M. Prevalence of HBs Antigen, and HCV and HIV Antibodies in a Young Male Population in Cameroon. Open J Gastroenterol. 2015;5(12):185-190. doi:10.4236/ ojgas.2015.512028.
  26. Foupouapouognigni Y, Mba SA, Betsem a Betsem E, et al. Hepatitis B and C virus infections in the three Pygmy groups in Cameroon. J Clin Microbiol. 2011;49(2):737-740. doi:10.1128/JCM.01475-10.
  27. Mbopi-Keou FX, Nkala IV, Kalla GC, et al. [Prevalence and factors associated with HIV and viral hepatitis B and C in the city of Bafoussam in Cameroon]. Pan Afr Med J. 2015;20:156. doi:10.11604/pamj.2015.20.156.4571.
  28. Noubiap JJ, Joko WY, Nansseu JR, Tene UG, Siaka C. Sero-epidemiology of human immunodeficiency virus, hepatitis B and C viruses, and syphilis infections among first-time blood donors in Edea, Cameroon. Int J Infect Dis. 2013;17(10):e832- 837. doi:10.1016/j.ijid.2012.12.007.
  29. Essome MC, Nsawir BJ, Nana RD, Molu P, Mohamadou M. [Sero-epidemiological study of three sexually transmitted infections: Chlamydia Trachomatis, Hepatitis B, Syphilis. A case study conducted at the Nkoldongo District Hospital in Yaounde]. Pan Afr Med J. 2016;25:244. doi:10.11604/pamj.2016.25.244.11107.
  30. Fouelifack Ymele F, Keugoung B, Fouedjio JH, Kouam N, Mendibi S, Dongtsa Mabou J. High Rates of Hepatitis B and C and HIV Infections among Blood Donors in Cameroon: A Proposed Blood Screening Algorithm for Blood Donors in Resource-Limited Settings. J Blood Transfus. 2012;2012:458372. doi:10.1155/2012/458372.
  31. Frambo AA, Atashili J, Fon PN, Ndumbe PM. Prevalence of HBsAg and knowledge about hepatitis B in pregnancy in the Buea Health District, Cameroon: a cross-sectional study. BMC Res Notes. 2014;7:394. doi:10.1186/1756-0500-7-394.
  32. Andre FE. Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine. Vaccine. 1990;8 Suppl:S74-78; discussion S79-80. doi:10.1016/0264-410X(90)90222-8.
  33. Laperche S, Boukatou G, Kouegnigan L, et al. Transfusion safety on the African continent: an international quality control of virus testing in blood banks. Transfusion. 2009;49(8):1600- 1608. doi:10.1111/j.1537-2995.2009.02239.x.